Principal Financial Group Inc. Has $9.01 Million Position in LivaNova PLC (NASDAQ:LIVN)

Principal Financial Group Inc. cut its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 19.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 171,402 shares of the company's stock after selling 41,335 shares during the quarter. Principal Financial Group Inc. owned approximately 0.32% of LivaNova worth $9,005,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Arizona State Retirement System grew its stake in LivaNova by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company's stock worth $828,000 after buying an additional 299 shares during the last quarter. Atria Investments Inc grew its position in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company's stock worth $297,000 after acquiring an additional 331 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock worth $328,000 after acquiring an additional 425 shares during the period. Rhumbline Advisers increased its holdings in shares of LivaNova by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 183,132 shares of the company's stock worth $10,039,000 after acquiring an additional 659 shares during the period. Finally, AQR Capital Management LLC lifted its position in LivaNova by 0.7% in the 2nd quarter. AQR Capital Management LLC now owns 129,871 shares of the company's stock valued at $7,103,000 after purchasing an additional 930 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on LIVN. Robert W. Baird upped their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Baird R W raised LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 25th. The Goldman Sachs Group assumed coverage on LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 price target for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $75.00 price objective on shares of LivaNova in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, LivaNova currently has an average rating of "Buy" and an average price target of $69.17.

Insider Activity

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company's stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company's stock.

LivaNova Price Performance

LIVN stock traded up $0.61 during trading hours on Tuesday, hitting $46.31. 261,713 shares of the stock traded hands, compared to its average volume of 605,452. The stock has a 50-day simple moving average of $50.65 and a 200 day simple moving average of $50.71. The company has a market cap of $2.51 billion, a P/E ratio of 110.26 and a beta of 0.98. LivaNova PLC has a one year low of $43.15 and a one year high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.